Repligen to Report Third Quarter 2023 Financial Results
October 17, 2023 07:30 ET
|
Repligen Corporation
WALTHAM, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its third quarter 2023 financial results on Tuesday, October 31,...
Repligen Appoints Olivier Loeillot as President and Chief Commercial Officer
October 02, 2023 07:30 ET
|
Repligen Corporation
WALTHAM, Mass., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has appointed...
Repligen Announces Agreement to Acquire Fluid Management Innovator Metenova
September 26, 2023 07:30 ET
|
Repligen Corporation
Proposed acquisition adds market leading magnetic mixing technology for upstream and downstream bioprocess applicationsExpands Repligen’s Fluid Management portfolio, complements single-use bag...
Repligen Appoints Jason K. Garland as Chief Financial Officer
September 12, 2023 07:30 ET
|
Repligen Corporation
WALTHAM, Mass., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has appointed...
Repligen Corporation to Present at Wells Fargo Healthcare Conference
September 01, 2023 07:30 ET
|
Repligen Corporation
WALTHAM, Mass., Sept. 01, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be...
Sartorius and Repligen Corporation Launch Integrated System with Biostat STR® and XCell® ATF for Upstream Process Intensification
August 17, 2023 08:00 ET
|
Repligen Corporation
Bioreactor and cell retention technology integration features a single direct control interface to simplify intensified seed train implementationCustomers experience optimized facility equipment...
Repligen Reports Second Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance
August 02, 2023 07:30 ET
|
Repligen Corporation
– Reports second quarter revenues of $159.2 million as reported, and base business revenues of $157.1 million, down 9% year-over-year – Adjusts full year revenue guidance to range of $635-$665...
Repligen to Report Second Quarter 2023 Financial Results
July 19, 2023 07:30 ET
|
Repligen Corporation
WALTHAM, Mass., July 19, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its second quarter 2023 financial results on Wednesday, August 2,...
Repligen Corporation to Present at Upcoming Investor Conferences
May 31, 2023 07:30 ET
|
Repligen Corporation
WALTHAM, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be...
Repligen Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance
May 02, 2023 07:30 ET
|
Repligen Corporation
Reports first quarter revenue of $182.7 million, with base business growth of 4% as reported and 7% at constant currencyReports first quarter gross margin of 55.2% on both GAAP and adjusted (non-GAAP)...